Celltrion, Inc.
068270
Rang in Aktien
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Aktienkurs
$146.63
Marktkapitalisierung
$33.44B
Veränderung (1 Tag)
-1.52%
Veränderung (1 Jahr)
23.60%
Land
KR
Handel Celltrion, Inc. (068270)
Kategorie
Healthcare
Operative Marge für Celltrion, Inc. (068270)
Operative Marge zum October 2026 TTM: 31.56%
Laut den neuesten Finanzberichten und dem Aktienkurs von Celltrion, Inc. beträgt die aktuelle operative Marge (TTM) 31.56%. Am Ende des Jahres 2024 lag die operative Marge bei 13.83%.
Historie der operativen Marge von Celltrion, Inc. von 2007 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 31.56% | 12.43% |
| 2025 | 28.07% | 102.96% |
| 2024 | 13.83% | -53.79% |
| 2023 | 29.93% | 5.61% |
| 2022 | 28.34% | -27.89% |
| 2021 | 39.30% | 1.13% |
| 2020 | 38.86% | 14.94% |
| 2019 | 33.81% | 2.77% |
| 2018 | 32.90% | -37.50% |
| 2017 | 52.64% | 41.35% |
| 2016 | 37.24% | -13.21% |
| 2015 | 42.91% | 0.33% |
| 2014 | 42.77% | -3.10% |
| 2013 | 44.14% | -20.91% |
| 2012 | 55.81% | -13.15% |
| 2011 | 64.26% | 9.06% |
| 2010 | 58.92% | 19.51% |
| 2009 | 49.30% | 34.08% |
| 2008 | 36.77% | 1,237.09% |
| 2007 | 2.75% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -98.78% |
US
|
|
| -149.01% | -104.72% |
US
|
|
| 25.57% | -99.19% |
AU
|
|
| 31.23% | -99.01% |
BE
|
|
| 28.81% | -99.09% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.